This is the most exciting part of the PR IMO.
"Results of these analyses demonstrated highly encouraging bioavailability via the oral route. Further studies in a mouse model, in which human ovarian cancer cell line OV90 was examined, showed both intraperitoneal and oral Kevetrin administration were successful in prolonging survival."
Phase 1 data showed strong correlations between human and mouse model. So I have no doubt that the oral dosing will produce similar data.
Oral K makes a great candidate for combination therapies because the other treatment is usually IV or radiation. It'll be much easier for the patients because they don't need to go through another round of IV treatment in K.
"Results of these analyses demonstrated highly encouraging bioavailability via the oral route. Further studies in a mouse model, in which human ovarian cancer cell line OV90 was examined, showed both intraperitoneal and oral Kevetrin administration were successful in prolonging survival."
Phase 1 data showed strong correlations between human and mouse model. So I have no doubt that the oral dosing will produce similar data.
Oral K makes a great candidate for combination therapies because the other treatment is usually IV or radiation. It'll be much easier for the patients because they don't need to go through another round of IV treatment in K.
3
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
